Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial
about
Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled TrialIntensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.Clinical use of the co-formulation of insulin degludec and insulin aspart.A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analy
P2860
Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Treatment intensification with ...... ed, controlled phase III trial
@en
Treatment intensification with ...... d, controlled phase III trial.
@nl
type
label
Treatment intensification with ...... ed, controlled phase III trial
@en
Treatment intensification with ...... d, controlled phase III trial.
@nl
prefLabel
Treatment intensification with ...... ed, controlled phase III trial
@en
Treatment intensification with ...... d, controlled phase III trial.
@nl
P2093
P2860
P921
P356
P1476
Treatment intensification with ...... ed, controlled phase III trial
@en
P2093
P2860
P304
P356
10.1111/DOM.12609
P577
2015-11-23T00:00:00Z